BIOARCTIC Aktie

 

STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and......

Stockholm, Sweden, June 26, 2025– BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is presented jointly by German Center for Neurodegenerative Diseases (DZNE) and the Piepenbrock Group. The award ceremony will take place in Bonn in November this year. "I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give...

STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST......

STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live online. Over the past 20 years, BioArctic has......

Stockholm, June 2, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live online. Over the past 20 years, BioArctic has built a thriving company based on a foundation of solid science and innovation, strong finances and an organization with well-educated staff and a value-driven corporate culture. At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on building Sweden's next major pharmaceutical...

Stockholm, May 30, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 3,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 3,000 options of series 2019/2028. As of May 30, 2025, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,531,485 shares, of which 74,131,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per...

Stockholm, 22 May 2025. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby the following resolutions were made. Adoption of the income statement and the balance sheet: allocation of result The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with the submitted accounting documents and resolved to allocate the funds available to the general meeting in accordance with the board of directors' proposal, i.e. that the available funds of SEK 889,598,575 shall be...

Stockholm, May 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) recommends granting orphan medicinal product designation to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. MSA is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect Events during the first quarter 2025 · FDA approved less frequent IV maintenance dosing of Leqembi® for the treatment of early Alzheimer's disease and accepted the Biologics License Application (BLA) for subcutaneous maintenance dosing of Leqembi in the US · Leqembi sales during BioArctic's partner Eisai's fiscal year 2024 (Apr-24 – Mar-25) exceeded EUR 200 M, resulting in a EUR 10 M milestone payment to BioArctic · The license agreement with Bristol Myers Squibb came...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding......

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding......

Stockholm, Sweden, May 15, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This would generate approximately SEK 510 M in royalty to BioArctic during the same period. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai...

STOCKHOLM, May 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January - March 2025 on Wednesday, May 21, 2025, at 08:00 a.m. CET. In conjunction to the report, BioArctic invites investors, analysts, and media to......

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System Atrophy (MSA) patients for treatment with the alpha-synuclein antibody exidavnemab in the......

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System Atrophy (MSA) patients for treatment with the alpha-synuclein antibody exidavnemab in the......

Stockholm, Sweden, May 1, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2025, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 14.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 101.7 million which is an increase of approximately 380 percent compared to the royalty obtained by BioArctic in Q1 2024. BioArctic's report for the first quarter 2025 will be published on May 21 at 08:00 CET. --- This...

Stockholm, April 30, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) have validated and will now evaluate a proposed Marketing Authorisation Variation for monthly lecanemab dosing in the United Kingdom. Maintenance dosing is an important step forward in providing flexibility to eligible patients and healthcare professionals. Leqembi is already approved in the UK for intravenous (IV) treatment every two weeks.[1] The proposed intravenous maintenance dosing variation application offers the...

Stockholm, April 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office, EPO, has issued a decision to grant European patent EP4172199B1 for exidavnemab, a drug candidate being developed as a treatment for synucleinopathies such as Parkinson's disease and Multiple System Atrophy (MSA). The patent enters into force on 14 May 2025 and expires in 2041, with the possibility of extension until 2046. Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson's disease and MSA. Exidavnemab is a...

The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday 22 May 2025   For more information on the content of the proposals, please see the complete notice to the Annual General Meeting below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar), and in Svenska Dagbladet and on the company's website within the next few days.   For more information, please contact: Anders Martin-Löf, CFO, 070 683 79 77, anders.martin-lof@bioarctic.com. NOTICE OF ANNUAL GENERAL...